Allarity Therapeutics, Inc. (ALLR)

NCM – Real Time Price. Currency in USD

1.30

+0.03 (2.36%)

At close: Jun 26, 2026, 4:00 PM EDT

1.33

+0.03 (2.07%)

After-hours: Jun 26, 2026, 7:58 PM EDT

03.06.2026

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.

15.05.2026

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP ® companion diagnostic - Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026

08.05.2026

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.

05.05.2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approval following FDA Fast Track designation All manufacturing-related payments completed; no additional cash outlays for manufacturing are anticipated TARPON SPRINGS, Fla., MAY 5, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion no later than the third quarter of 2026 at its world-class contract development and manufacturing organization (CDMO).

27.04.2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's DRP® companion diagnostic specific to stenoparib.

31.03.2026

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancer Durable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implemented Expansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced financial results for the year ended December 31, 2025.

06.03.2026

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital.

Videos

No Data

There is no data to display

Press releases

15.05.2026

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

05.05.2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

27.04.2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

31.03.2026

Allarity Therapeutics, Inc. (ALLR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Allarity Therapeutics, Inc. (ALLR)

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Videos

No Data

Press releases

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Videos

No Data

Press releases

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Search stocks

Allarity Therapeutics, Inc. (ALLR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Allarity Therapeutics, Inc. (ALLR)

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Videos

No Data

Press releases

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Videos

No Data

Press releases

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress